Privia Health Group, Inc. (PRVA)

NASDAQ: PRVA · USD

$21.8

-0.02 (-0.1%)· Recorded snapshot

Market cap	2.8B
Revenue (ttm)	2.4B
Net income (ttm)	28.1M
EPS (ttm)	$0.22
Shares out	127.7M
P/E (trailing)	99.5x
P/E (forward)	57.3x
Volume	482,300
Beta	0.80

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2.4B
Net income (ttm): 28.1M
EPS (ttm): $0.22
P/E (trailing): 99.5x
P/E (forward): 57.3x
Market cap: 2.8B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Giữ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E57.3

P25 13.4P50 20.2P75 35.7

Trailing P/E99.5

P25 15.4P50 25.8P75 43.5

ROE4.3

P25 -113.8P50 -46.5P75 -0.9

ROIC6.5

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All PRVA indicators

Market & fundamental data

Available fields

254

Groups with data

Currency

USD

Showing 254 of 254 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001759655
Company name	Privia Health Group, Inc.
Country	United States
Country code	US
CUSIP number	74276R102
Earnings date	2026-11-05
Earnings time	bmo
Employees	1,226
Employees change	86
Employees growth	7.54%
Enterprise value	$2.4B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2007
In index	RUSSELL2000
Industry	Health Information Services
IPO date	2021-04-29
Is primary listing	Yes
Is SPAC	No
ISIN number	US74276R1023
Last 10-K release date	2026-02-27
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$2.8B
Market cap category	Mid-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$21.81
Price currency	USD
Sector	Healthcare
SIC code	8000
Stock price date	2026-10-28
Symbol	PRVA
U.S. state	Virginia
Website	https://www.priviahealth.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	23.71x
Average P/E ratio (3Y)	139.53x
Average P/E ratio (5Y)	139.9x
Earnings yield	1.01%
EV/Earnings	85.39x
EV/EBIT	53.52x
EV/EBITDA	42.18x
EV/FCF	18.31x
EV/Sales	1.02x
FCF / EV yield	5.46%
FCF yield	4.67%
Forward EV/Sales	0.94x
Forward P/E	57.29x
Forward P/S	1.1x
Graham number	5.52843
Graham upside	-74.83%
Industry forward P/E	34.62x
Lynch fair value	$1.10
Lynch upside	-95.01%
P/(FCF - SBC) ratio	50.65x
P/(OCF - SBC) ratio	50.65x
P/B ratio	3.52x
P/E ratio	99.46x
P/FCF ratio	21.39x
P/OCF ratio	21.39x
P/S ratio	1.19x
Price / tangible book value	8.06x
Price/EBITDA ratio	49.27x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	1.9%
EBITDA margin	2.41%
Effective tax rate	39.69%
FCF margin	5.56%
Gross margin	10.03%
Operating margin	1.9%
Pretax margin	2.38%
Profit margin	1.19%
Profit per employee	$22,940
Profitable quarters	16
Profitable years	3
Revenue per employee	$1.9M
ROA	2.03%
ROA (5Y)	-4.85%
ROCE	5.25%
ROE	4.31%
ROE (5Y)	-11.26%
ROIC	6.52%
ROIC (5Y)	-30.26%
SBC / revenue	3.21%
Tax / revenue	0.94%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	99.55%
EPS growth (Q)	250.01%
EPS growth (QoQ)	250%
EPS growth 3Y	-8.74%
EPS growth quarters	1
EPS growth years	1
FCF growth	42.75%
FCF growth (Q)	-86.2%
FCF growth 3Y	49.19%
FCF growth 5Y	28.99%
Gross profit growth	24.93%
Gross profit growth (Q)	24.97%
Gross profit growth 3Y	16.05%
Gross profit growth 5Y	32.68%
Net income growth	89.5%
Net income growth (Q)	236.73%
Net income growth (QoQ)	195.3%
Net income growth 3Y	-6.13%
Net income growth quarters	1
Net income growth years	1
OCF growth	42.75%
OCF growth (Q)	-86.2%
OCF growth 3Y	49.15%
OCF growth 5Y	28.85%
Operating income growth	128.78%
Operating income growth (Q)	252.91%
Operating income growth 3Y	58.04%
Revenue growth	24.1%
Revenue growth (Q)	21.39%
Revenue growth (QoQ)	4.77%
Revenue growth 3Y	16.1%
Revenue growth 5Y	22.35%
Revenue growth quarters	22
Revenue growth years	7

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$12.1M
EBIT	$44.9M
EBITDA	$56.9M
EPS	$0.22
FCF per share	$1.03
Financing cash flow	$-5.1M
Free cash flow	$131.1M
Free cash flow minus SBC	$55.4M
Gross profit	$236.5M
Income taxes	$22.3M
Investing cash flow	$-104M
Net cash flow	$22.1M
Net income	$28.1M
Operating cash flow minus SBC	$55.4M
Operating income	$44.9M
Revenue	$2.4B
Stock-based compensation	$75.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	4.47
Book value per share	$6.19
Debt / EBITDA	0.14
Debt / equity	0.01
Debt / FCF	0.07
Goodwill	$215.8M
Long-term assets	$463.3M
Long-term liabilities	$16.1M
Net cash (debt)	$403.5M
Net cash / market cap	14.38%
Net cash growth	5.21%
Net debt / EBITDA	-7.09
Net debt / equity	-0.48
Net debt / FCF	-3.08
Piotroski F-Score	6
Property, plant and equipment	$8.3M
Shareholders' equity	$838.1M
Tangible book value	$347.9M
Tangible book value per share	$2.75
Total assets	$1.5B
Total cash	$412.2M
Total debt	$8.7M
Total liabilities	$650.5M
WACC	8.64%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.71
Current assets	$1B
Current liabilities	$634.4M
Current ratio	1.62
Net working capital	$-19.3M
Quick ratio	1.55
Working capital	$390.8M
Working capital turnover	6.38

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.73%
Dividend yield	0%
Shareholder yield	-2.73%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$22.72
1D price change	-0.09%
1M price change	10.15%
1M total return	10.15%
1W price change	-5.32%
1W total return	-5.32%
1Y price change	-15.62%
1Y return CAGR	-15.63%
1Y total return	-15.62%
20-day SMA	$21.56
200-day SMA	$22.68
3M price change	-12%
3M total return	-12%
3Y price change	-0.55%
3Y return CAGR	-0.18%
3Y total return	-0.55%
50-day SMA	$20.86
50-day SMA vs 200-day SMA	50under200
52-week high	$28.82
52-week high date	2026-07-16
52-week low	$18.92
52-week low date	2026-09-24
5Y price change	-8.67%
5Y return CAGR	-1.8%
5Y total return	-8.67%
6M price change	-11.06%
6M total return	-11.06%
All-time high	$50.77
All-time high date	2021-06-29
All-time low	$15.92
All-time low date	2024-05-21
Average true range (ATR)	$0.61
Average volume	1.2M
Beta (1Y)	0.42
Beta (2Y)	0.67
Beta (5Y)	0.8
Change from 52-week high	-24.32%
Change from 52-week low	15.31%
Change from all-time high	-57.24%
Change from all-time low	36.37%
Change from open	-0.27%
Day's gap	0.18%
Dollar volume	$10.5M
High price	$21.96
Low price	$21.67
Monthly RSI	48.23
Open price	$21.87
Position in 52-week range	48.28%
Previous close	$21.83
Price vs 150-day SMA	-4.43%
Price vs 20-day SMA	0.71%
Price vs 200-day SMA	-4.27%
Price vs 50-day SMA	4.07%
Relative volume	0.41
Return from IPO open	-26.8%
Return from IPO price	-4.52%
RSI	52.35
Sharpe ratio	-0.5
Sharpe ratio (3Y)	0.06
Sharpe ratio (5Y)	0.09
Sortino ratio	-0.54
Sortino ratio (3Y)	0.25
Sortino ratio (5Y)	0.26
Volume	482.3K
Weekly RSI	47.81
YTD price change	-8.44%
YTD total return	-8.44%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	108.9M
Float percentage	85.29%
Shares change (QoQ)	0.72%
Shares change (YoY)	2.73%
Shares held by insiders	0.49%
Shares held by institutions	81.43%
Shares outstanding	127.7M
Short % of float	5.33%
Short % of shares	4.55%
Short ratio	4.5 days

Deeper analysis on PRVA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this PRVA report

Is a complete PRVA research report available?

No complete published report is available for Privia Health Group, Inc. (PRVA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Privia Health Group, Inc. (PRVA)

Price

Financial snapshot

Fair-value bridge

Latest news · PRVA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All PRVA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on PRVA

Frequently asked questions